| 51. |
|
|
| 52. |
|
|
| 53. |
|
|
| 54. |
- Caselli, P., et al.
(författare)
-
Water vapor toward starless cores : The Herschel view
- 2010
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 521, s. L29-
-
Tidskriftsartikel (refereegranskat)abstract
- Aims: Previous studies by the satellites SWAS and Odin provided stringent upper limits on the gas phase water abundance of dark clouds (x(H2O) < 7 × 10-9). We investigate the chemistry of water vapor in starless cores beyond the previous upper limits using the highly improved angular resolution and sensitivity of Herschel and measure the abundance of water vapor during evolutionary stages just preceding star formation. Methods: High spectral resolution observations of the fundamental ortho water (o-H2O) transition (557 GHz) were carried out with the Heterodyne Instrument for the Far Infrared onboard Herschel toward two starless cores: Barnard 68 (hereafter B68), a Bok globule, and LDN 1544 (L1544), a prestellar core embedded in the Taurus molecular cloud complex. Detailed radiative transfer and chemical codes were used to analyze the data. Results: The RMS in the brightness temperature measured for the B68 and L1544 spectra is 2.0 and 2.2 mK, respectively, in a velocity bin of 0.59 km s-1. The continuum level is 3.5 ± 0.2 mK in B68 and 11.4 ± 0.4 mK in L1544. No significant feature is detected in B68 and the 3σ upper limit is consistent with a column density of o-H2O N(o-H2O) < 2.5 × 1013 cm-2, or a fractional abundance x(o-H2O) < 1.3 × 10-9, more than an order of magnitude lower than the SWAS upper limit on this source. The L1544 spectrum shows an absorption feature at a 5σ level from which we obtain the first value of the o-H2O column density ever measured in dark clouds: N(o-H2O) = (8 ± 4) × 1012 cm-2. The corresponding fractional abundance is x(o-H2O) ≃ 5 × 10-9 at radii >7000 AU and ≃2 × 10-10 toward the center. The radiative transfer analysis shows that this is consistent with a x(o-H2O) profile peaking at ≃10-8, 0.1 pc away from the core center, where both freeze-out and photodissociation are negligible. Conclusions: Herschel has provided the first measurement of water vapor in dark regions. Column densities of o-H2O are low, but prestellar cores such as L1544 (with their high central densities, strong continuum, and large envelopes) appear to be very promising tools to finally shed light on the solid/vapor balance of water in molecular clouds and oxygen chemistry in the earliest stages of star formation. Herschel is an ESA space observatory with science instruments provided by European-led Principal Investigator consortia and with important participation from NASA.
|
|
| 55. |
- Ceccarelli, C., et al.
(författare)
-
Herschel spectral surveys of star- forming regions Overview of the 555-636 GHz range
- 2010
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 521, s. L22-
-
Tidskriftsartikel (refereegranskat)abstract
- High resolution line spectra of star-forming regions are mines of information: they provide unique clues to reconstruct the chemical, dynamical, and physical structure of the observed source. We present the first results from the Herschel key project " Chemical HErschel Surveys of Star forming regions", CHESS. We report and discuss observations towards five CHESS targets, one outflow shock spot and four protostars with luminosities bewteen 20 and 2 x 105 L similar to : L1157-B1, IRAS 16293-2422, OMC2-FIR4, AFGL 2591, and NGC 6334I. The observations were obtained with the heterodyne spectrometer HIFI on board Herschel, with a spectral resolution of 1 MHz. They cover the frequency range 555-636 GHz, a range largely unexplored before the launch of the Herschel satellite. A comparison of the five spectra highlights spectacular differences in the five sources, for example in the density of methanol lines, or the presence./absence of lines from S-bearing molecules or deuterated species. We discuss how these differences can be attributed to the different star-forming mass or evolutionary status.
|
|
| 56. |
- Chen, Jo-Hsin, et al.
(författare)
-
HERSCHEL HIFI OBSERVATIONS OF O-2 TOWARD ORION: SPECIAL CONDITIONS FOR SHOCK ENHANCED EMISSION
- 2014
-
Ingår i: Astrophysical Journal. - 1538-4357 .- 0004-637X. ; 793:2, s. Article nr. 111 -
-
Tidskriftsartikel (refereegranskat)abstract
- We report observations of molecular oxygen (O-2) rotational transitions at 487 GHz, 774 GHz, and 1121 GHz toward Orion Peak A. The O-2 lines at 487 GHz and 774 GHz are detected at velocities of 10-12 km s(-1) with line widths similar to 3 km s(-1); however, the transition at 1121 GHz is not detected. The observed line characteristics, combined with the results of earlier observations, suggest that the region responsible for the O-2 emission is similar or equal to 9" (6 x 10(16) cm) in size, and is located close to the H-2 Peak 1 position (where vibrationally excited H-2 emission peaks), and not at Peak A, 23" away. The peak O-2 column density is similar to 1.1 x 10(18) cm(-2). The line velocity is close to that of the 621 GHz water maser emission found in this portion of the Orion Molecular Cloud, and having a shock with velocity vector lying nearly in the plane of the sky is consistent with producing maximum maser gain along the line of sight. The enhanced O-2 abundance compared to that generally found in dense interstellar clouds can be explained by passage of a low-velocity C shock through a clump with preshock density 2 x 10(4) cm(-3), if a reasonable flux of UV radiation is present. The postshock O-2 can explain the emission from the source if its line-of-sight dimension is similar or equal to 10 times larger than its size on the plane of the sky. The special geometry and conditions required may explain why O-2 emission has not been detected in the cores of other massive star-forming molecular clouds.
|
|
| 57. |
- Colleoni, M, et al.
(författare)
-
Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor.
- 2005
-
Ingår i: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. - : Elsevier BV. - 0923-7534. ; 16:5, s. 716-25
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Controversy persists about whether chemotherapy benefits all breast cancer patients. PATIENTS AND METHODS: In the International Breast Cancer Study Group (IBCSG) trial VII, 1212 postmenopausal patients with node-positive disease were randomized to receive tamoxifen for 5 years or tamoxifen plus three concurrent courses of cyclophosphamide, methotrexate and 5-fluorouracil ('classical' CMF) chemotherapy, either early, delayed or both. In IBCSG trial IX, 1669 postmenopausal patients with node-negative disease were randomized to receive either tamoxifen alone or three courses of adjuvant classical CMF prior to tamoxifen. Results were assessed according to estrogen receptor (ER) content of the primary tumor. RESULTS: For patients with node-positive, ER-positive disease, adding CMF either early, delayed or both reduced the risk of relapse by 21% (P=0.06), 26% (P=0.02) and 25% (P=0.02), respectively, compared with tamoxifen alone. There was no difference in disease-free survival when CMF was given prior to tamoxifen in patients with node-negative, ER-positive tumors. CONCLUSIONS: CMF given concurrently (early, delayed or both) with tamoxifen was more effective than tamoxifen alone for patients with node-positive, endocrine-responsive breast cancer, supporting late administration of chemotherapy even after commencement of tamoxifen. In contrast, sequential CMF and tamoxifen for patients with node-negative, endocrine-responsive disease was ineffective.
|
|
| 58. |
|
|
| 59. |
- Curigliano, G, et al.
(författare)
-
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
- 2017
-
Ingår i: Annals of oncology : official journal of the European Society for Medical Oncology. - : Elsevier BV. - 1569-8041. ; 28:8, s. 1700-1712
-
Tidskriftsartikel (refereegranskat)abstract
- The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer. Treatments were assessed in light of their intensity, duration and side-effects, seeking where appropriate to escalate or de-escalate therapies based on likely benefits as predicted by tumor stage and tumor biology. The Panel favored several interventions that may reduce surgical morbidity, including acceptance of 2mm margins for DCIS, the resection of residual cancer (but not baseline extent of cancer) in women undergoing neoadjuvant therapy, acceptance of sentinel node biopsy following neoadjuvant treatment of many patients, and the preference for neoadjuvant therapy in HER2 positive and triple-negative, stage II and III breast cancer. The Panel favored escalating radiation therapy with regional nodal irradiation in high-risk patients, while encouraging omission of boost in low-risk patients. The Panel endorsed gene expression signatures that permit avoidance of chemotherapy in many patients with ER positive breast cancer. For women with higher risk tumors, the Panel escalated recommendations for adjuvant endocrine treatment to include ovarian suppression in premenopausal women, and extended therapy for postmenopausal women. However, low-risk patients can avoid these treatments. Finally, the Panel recommended bisphosphonate use in postmenopausal women to prevent breast cancer recurrence. The Panel recognized that recommendations are not intended for all patients, but rather to address the clinical needs of the majority of common presentations. Individualization of adjuvant therapy means adjusting to the tumor characteristics, patient comorbidities and preferences, and managing constraints of treatment cost and access that may affect care in both the developed and developing world.
|
|
| 60. |
|
|
